SCHEMBL3799212

SCHEMBL3799212

O=C(O)[C@H]1C[C@H](S(=O)(=O)c2ccccc2Cl)C[C@@H]1OCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 3/20 0.40
S1PR5 Q9H228 3/20 0.40
CTSS P25774 2/20 0.40
HTR2A P28223 1/20 0.40
KCNH2 Q12809 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
GRM2 Q14416 5/20 0.38
GRM3 Q14832 5/20 0.38
GRM8 O00222 1/20 0.37
GRM6 O15303 1/20 0.37
GRM7 Q14831 1/20 0.37
MMP9 P14780 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
ALDH1A1 P00352 1/20 0.36
TACR1 P25103 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15654692 1.00 S1PR1 (0.40) S1PR1S1PR5CTSSHTR2AKCNH2
SCHEMBL3794163 1.00 S1PR1 (0.40) S1PR1S1PR5CTSSHTR2AKCNH2
SCHEMBL3804154 0.91 FFAR4 (0.40) S1PR1S1PR5CTSSSIGMAR1GRM2
SCHEMBL3798978 0.91 FFAR4 (0.40) S1PR1S1PR5CTSSSIGMAR1GRM2
SCHEMBL3803526 0.89 CTSS (0.39) CTSSALDH1A1TACR1FFAR4NPSR1
SCHEMBL3797236 0.89 CTSS (0.39) CTSSALDH1A1TACR1FFAR4NPSR1
SCHEMBL3802518 0.88 CTSS (0.38) CTSSALDH1A1TACR1FFAR4
SCHEMBL3797958 0.88 CTSS (0.38) CTSSALDH1A1TACR1FFAR4
SCHEMBL1140303 0.88 CTSS (0.40) CTSSALDH1A1FFAR4
SCHEMBL1139765 0.82 CTSS (0.54) CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440521-B1 NOVEL CYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-04-30 EP claimed
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 US claimed
EP-2440521-B1 NOVEL CYCLOPENTANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-04-30 EP disclosed
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317647-A1 NOVEL CYCLOPENTANE DERIVATIVES TBXA2R, ADORA1, CNR1 S1PR1 269/4885S1PR5 334/4885CTSS 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.